Windlas Biotech's Q1 FY 2025-26 Quarterly Results

Result Summary

• Windlas Biotech Ltd reported a 22.5% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 20.1%.
• Its expenses for the quarter were up by 25.5% QoQ and 19.3% YoY.
• The net profit increased 3.9% QoQ and increased 31.0% YoY.
• The earnings per share (EPS) of Windlas Biotech Ltd stood at 8.3 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Windlas Biotech Ltd is a prominent player in the pharmaceutical industry, primarily engaged in the manufacturing and distribution of pharmaceutical formulations. The company provides a wide range of services, including contract development and manufacturing, focusing on generic products and new drug delivery systems. While specific recent developments about Windlas Biotech Ltd are not provided in the current dataset, the company has been recognized for its dedication to innovation in pharmaceutical manufacturing and development. Operating in a competitive industry, Windlas Biotech aims to leverage its technical expertise and state-of-the-art manufacturing facilities to enhance its market position.

Revenue

In the first quarter of fiscal year 2026 (Q1FY26), Windlas Biotech Ltd reported a total income of ₹215.33 crores. This represents a significant quarter-over-quarter (QoQ) increase of 22.5% from ₹175.72 crores in the fourth quarter of fiscal year 2025 (Q4FY25). The year-over-year (YoY) growth from the first quarter of fiscal year 2025 (Q1FY25), where total income was ₹179.29 crores, stands at 20.1%. The robust growth in total income highlights the company's ability to effectively capture market opportunities and expand its revenue base during this period.

Profitability

During Q1FY26, Windlas Biotech Ltd achieved a profit before tax (PBT) of ₹23.26 crores, reflecting a modest QoQ growth of 2.8% from ₹22.63 crores in Q4FY25. On a YoY basis, the PBT increased by 27.0% compared to ₹18.31 crores in Q1FY25. The company’s profit after tax (PAT) for the same period was ₹17.66 crores, which marks a QoQ rise of 3.9% from ₹16.99 crores in the previous quarter and a YoY increase of 31.0% from ₹13.48 crores in Q1FY25. The earnings per share (EPS) for Q1FY26 is reported at ₹8.30, showing a QoQ growth of 2.5% from ₹8.10 and a YoY improvement of 29.7% from ₹6.40. This performance underscores the company's ability to maintain profitability growth despite fluctuations in market conditions.

Operating Metrics

In Q1FY26, Windlas Biotech Ltd reported total expenses of ₹192.08 crores, which represents a 25.5% QoQ increase from ₹153.10 crores in Q4FY25. Compared to the same quarter in the previous year, when expenses were ₹160.97 crores, the YoY increase was 19.3%. The tax expense for Q1FY26 was ₹5.59 crores, slightly decreasing by 0.9% from ₹5.64 crores in Q4FY25, yet reflecting a 15.7% increase from ₹4.83 crores in Q1FY25. These metrics provide insights into the company's operational efficiency and cost management strategies during this period.